×
Biomerica Total Long-Term Assets 2010-2024 | BMRA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biomerica total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
View More
Biomerica Total Long-Term Assets 2010-2024 | BMRA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Biomerica total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$79.7B
Takeda Pharmaceutical (TAK)
$42.4B
Sandoz Group AG (SDZNY)
$19.3B
Merck (MKKGY)
$18.8B
Astellas Pharma (ALPMY)
$18.3B
United Therapeutics (UTHR)
$16.4B
Summit Therapeutics (SMMT)
$13.6B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$11.8B
Catalent (CTLT)
$10.8B
Jazz Pharmaceuticals (JAZZ)
$7.6B
Madrigal Pharmaceuticals (MDGL)
$7.2B
Orion OYJ (ORINY)
$6.7B
Corcept Therapeutics (CORT)
$5.9B
Ionis Pharmaceuticals (IONS)
$5.4B
Crinetics Pharmaceuticals (CRNX)
$5.3B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2.4B
Arrowhead Pharmaceuticals (ARWR)
$2.3B
Centessa Pharmaceuticals (CNTA)
$2.1B
Evotec AG (EVO)
$1.9B
NewAmsterdam Pharma (NAMS)
$1.9B
Xencor (XNCR)
$1.7B
Recursion Pharmaceuticals (RXRX)
$1.6B
Harrow (HROW)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Cassava Sciences (SAVA)
$1.5B